In September - Sofiva Genomics launched new cancer-detection products.

Sofiva Genomics launched genetic testing products for four different types of cancer (breast cancer, colorectal cancer, cholangiocarcinoma, and urothelial carcinoma). Using next-generation sequencing technology to detect genes related to various types of cancer, Sofiva Genomics helps to develop subsequent cancer treatment plans.

In September - Sofiva Genomics upgraded its cancer products.

Sofiva Genomics upgraded its "Cancer Monitor Gene Test V1.0" and "Prostate Cancer Gene Test" products, adding new target genes to provide testers with a broader range of clinical applications.

In August - Sofiva Genomics introduced the "Roche Diagnostics" Automated Next Generation Sequencing Library Instrument.

This instrument efficiently simplifies more than 100 operating steps, reduces labor burden, and helps improve the accuracy of subsequent next-generation sequencing tests.

In May - Sofiva Genomics collaborated with Cathay Life Insurance to integrate genetic testing products into insurance in-kind payments.

Sofiva Genomics pioneered the integration of "Cancer Monitor Gene Test  V2.2" into insurance in-kind payments. Using Roche Diagnostics reagents for genetic testing facilitates the evaluation of treatment efficacy and monitoring of cancer recurrence or metastasis.

In March - Sofiva Genomics Medical Laboratory obtained ISO 15189: Medical Laboratories accreditation.

Sofiva Genomics Medical Laboratory has internationally recognized its testing quality.

In January - Sofiva Genomics collaborated with the Taiwan Foundation for Rare Disorders to create a public welfare desk calendar and curate an exhibition.

In 2023, with the theme of "Leaping," Sofiva Genomics provided public welfare sponsorship for patients to create painting desk calendars and curate exhibitions to support patients with practical actions.

In January - Sofiva Genomics received recognition for continuing the "Symbol of National Quality (SNQ)" certification.

Our " Sofiva Non-Invasive Prenatal Screening," "Sofiva Carrier Scan" ,"Sofiva Cancer Monitor," and " Sofiva Baby Scan," won the "Symbol of National Quality (SNQ)" continuing certification.

In December - The College of American Pathologists (CAP) Laboratory approved to pass extending Sofiva Genomics accreditation.

Sofiva Genomics is compliant with CAP international standards.

In  February -  Sofiva Genomics launched the Sofiva Homologous Recombination Deficiency (HRD) testing.

Sofiva Genomics cooperated with international manufacturer SOPHiA GENETICS technology and launched an HRD test using Illumina sequencing and array technologies.

In January - Sofiva Genomics collaborated with the Down Syndrome Foundation to create a public welfare desk calendar and curation.   

Sofiva Genomics collaborated with the Down Syndrome Foundation for a public welfare art exhibition and creative 2022 desk calendars to see the diversity of life together.

In December - Sofiva Genomics received recognition for the "Symbol of National Quality(SNQ)" certification.

"Sofiva Cancer Monitor" and "Sofiva Baby Scan"  won the"Symbol of National Quality(SNQ)" certification.

In December - Sofiva Genomics received recognition for continuing the "Symbol of National Quality(SNQ)" certification.

In October - Sofiva Genomics added the ISO/IEC 17025 certification project.

The certification includes "Sofiva Baby Scan," "Next Generation Sequencing of Preimplantation Genetic Testing for Aneuploidy (embryo tissue fluid)," "Liquid and Tissue Biopsy Genetic Testing (249 genes)," and "Human Genetic Disorders and Cancer-related Genome Testing - Next Generation Sequencing (genetic cancer-related genome and hearing loss related genome).

In  September - Sofiva Genomics passed the LDTS record and registered authentication with the Taiwan Food and Drug Administration of the Ministry of Health and Welfare.

Recognized by the central authorities, Sofiva Genomics Medical Laboratory successfully recorded and registered authentication for Laboratory Developed Tests and Services (LDTS)  to provide safe and guaranteed testing quality.

In September - Sofiva Genomics launched a new genome and BRCA1/2 ctDNA genetic testing for prostate cancer.

Sofiva Genomics led the industry and officially launched a genome and BRCA1/2 ctDNA genetic testing explicitly designed for targeted prostate cancer therapy.

In December- Sofiva Genomics passed the College of American Pathologists (CAP) laboratory accreditation. 

A CAP-accredited testing unit is equivalent to an internationally standardized laboratory, and people can use it as a basis for the public to evaluate excellent testing units.

In December - Sofiva Genomics received recognition for continuing the "Symbol of National Quality(SNQ)" certification.
" Sofiva Non-Invasive Prenatal Screening" and " Sofiva Carrier Scan" won the "Symbol of National Quality(SNQ)" continuing certification.

In April - Sofiva Genomics Medical Laboratory complied with the international standards ISO/IEC 17025:2017 and the Chinese National Standard (CNS) 17025:2018.

The new items' certifications include "Liquid and Tissue Biopsy Genetic Testing,"  "Genetic Test-Whole Genome Sequencing and  Next Generation Sequencing," "Carrier Scan," and "Non-Invasive Prenatal Screening."

In February - Sofiva Genomics's Thai subsidiary moved to the Bangkok business district.

In December - Sofiva Non-Invasive Prenatal Screening won the National Innovation Award.

Sofiva Non-Invasive Prenatal Screening won the award, which is the highest indicator award for domestic biomedical and health research and development results.

In December - Sofiva Carrier Scan won the Symbol of National Quality (SNQ). 

In October - Sofiva Genomics won the 28th National Award of Outstanding.

In March - Sofiva Genomics launched Sofiva Carrier Scan.

In January-Sofiva Genomics establoshed Thailand subsidiary.

In November - Yi-ning Su, founder of Sofiva Genomics, won the 41st Model of Entrepreneurs Award.

In November- Sofiva Genomics launched Sofiva Cancer Scan and Sofiva Cancer Risk.

In July - Sofiva Genomics relocated to 27 Baoqing Road, Taipei City.

Sofiva Genomics moved to Taiwan's first curtain wall building, the Asia Cement Building, to decipher human genes among classical architecture.

In May - Sofiva Genomics launched three cancer genetic testings: cancer-targeted therapy+, cancer monitor+, and cancer follow-up. 

Sofiva Genomics adopted advanced Illumina genetic testing-whole genome sequencing from the NGS platform and utilized Liquid Biopsy of international manufacture Roche patented detection technology.

In January - Sofiva Genomics (6615) officially listed on the over-the-counter market.

Sofiva Genomics Co., Ltd. (stock code 6615) officially listed on the over-the-counter market on January 22.

In November - Sofiva Genomics held its annual artist desk calendar public welfare activity.

Sofiva Genomics cooperated with the Taiwan Arts Development Association for the Disabled to carry out artist desk calendar public welfare activity.

In October - Sofiva Genomics signed official contracts with Vietnam and Indonesia.

Sofiva Genomics added overseas layouts to sign official distribution contracts with Vietnam and Indonesia.

In July - Sofiva Genomics (6615) officially applied for the over-the-counter market.

Sofiva Genomics Co., Ltd. (stock code 6615) officially applied for the over-the-counter market on July 31.

In May - Sofiva Genomics fully upgraded and launched the Non-Invasive Prenatal Screening (NIPS+).

In February - Sofiva Genomics Medical Laboratory passed the ISO/IEC 17025 extension certification from the Taiwan Accreditation Foundation (TAF).

In January - Sofiva Genomics (6615) officially listed on the emerging stock market.

In September - Sofiva Genomics received the bronze award in the 

"Biomedical Group" of the Taiwan Healthcare and Agricultural Biotech Industries Innovation Award and is the only award-winning company in the field of genetic testing.

In May - Sofiva Genomics and UCLA HEALTH-CTI Medical Laboratories signed a cooperation agreement.

Sofiva Genomics signed a cooperation agreement with UCLA HEALTH-CTI Medical Laboratories to provide complete product technical and market support and lay out the Chinese market.

In March - Sofiva Genomics fully launched a screening for newborn congenital cytomegalovirus infection.

In October -  Sofiva Genomics Non-Invasive Prenatal Screening (NIPS+) won the "Enterprises Innovation Award of the National Innovation Award."

In September - Sofiva Genomics was recognized as an "Outstanding Enterprise" by the National Brand Yushan Award.

In September - Sofiva Genomics obtained the only global gene leader Illumina patent certification. 

Sofiva Genomics is the only Non-Invasive Prenatal Screening technology certification unit that has obtained a patent from Illumina, a global gene leader.

In March - Sofiva Genomics fully released a  Human Papillomavirus Screening (HPV Screening).

In December- Sofiva Genomics fully released a next generation sequencing-based preimplantation genetic screening (NGS-based PGS).

With international standards, Sofiva Genomics applied next-generation sequencing in maternal-fetal medicine and reproductive medicine.

In December- Sofiva Genomics Non-Invasive Prenatal Screening (NIPS+) was awarded the "National Biotechnology and Medicine Care Quality Award" and the "Symbol of National Quality (SNQ)" double certification.

In March - Sofiva Genomics received recognition for "Top 10 Outstanding Enterprises" and "Top 10 Outstanding Products" at the Golden Peak Award.

In December  - Sofiva Genomics received recognition for "Top 10 Potential Enterprises" and "Top 10 Potential Products" at the Golden Torch Award.

In October - Sofiva Genomics Medical Laboratory obtained ISO/IEC 17025 international recognition from the Taiwan Accreditation Foundation (TAF).

In June - Sofiva Genomics cooperated with the Taiwan Foundation for Rare Disorders to provide rare disease-related testing services.

In March - Sofiva Genomics fully released preeclampsia risk screening.

In November - Sofiva Genomics Medical Laboratory passed ISO 9001 national certification.

In November - Sofiva Genomics completed Non-Invasive Prenatal Screening (NIPS) in Taiwan.

In October - Dr. Su Yining, Chairman of Sofiva Genomics, accepted an interview with Discovery's "National New Movement - Technology Storks."

In July- Sofiva Genomics Co., Ltd. was established at the National Taiwan University Innovation & Incubation Center.